Actively Recruiting
Finerenone Therapy for Pediatric HSPN With Mild Proteinuria
Led by Capital Institute of Pediatrics, China · Updated on 2026-01-07
116
Participants Needed
1
Research Sites
150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease. Currently, the treatment for children with mild proteinuria HSPN mainly involves ACEI/ARB, but long-term use of these drugs can lead to an increase in aldosterone levels, affecting therapeutic efficacy. Finerenone can improve vascular endothelial cell dysfunction and renal tissue inflammation and fibrosis, and reduce urinary protein in patients with glomerular diseases. This study intends to conduct an exploratory randomized controlled clinical trial of finerenone in children with HSPN accompanied by a small amount of proteinuria to evaluate the efficacy and safety of finerenone treatment.
CONDITIONS
Official Title
Finerenone Therapy for Pediatric HSPN With Mild Proteinuria
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children aged over 3 years and under 18 years
- Diagnosed with Henoch-Schönlein purpura nephritis (HSPN)
- 24-hour urine protein between 8 mg/h/m2 and less than 20 mg/h/m2 body surface area (or 300 mg/d to less than 1000 mg/d)
- Signed informed consent form
You will not qualify if you...
- Abnormal kidney function with eGFR less than 90 ml/min/1.73m2 body surface area
- Renal pathological grade IV or higher
- Use of glucocorticoids and/or immunosuppressants within the past 2 weeks
- Recent use of high-dose glucocorticoids for more than two weeks
- Liver transaminase levels more than twice the upper limit of normal
- Severe heart failure
- Concurrent use of CYP4A inhibitors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Capital Center for Children's Health,Capital Medical University
Beijing, Beijing Municipality, China, 100020
Actively Recruiting
Research Team
Y
Yue Jia
CONTACT
J
Juan Tu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here